ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. More Details
Adequate balance sheet and overvalued.
Share Price & News
How has ScandiDos's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2FV has not had significant price volatility in the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: 2FV underperformed the German Medical Equipment industry which returned 20.7% over the past year.
Return vs Market: 2FV underperformed the German Market which returned 4.2% over the past year.
Price Volatility Vs. Market
How volatile is ScandiDos's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is ScandiDos undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 2FV's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 2FV's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 2FV is unprofitable, so we can't compare its PE Ratio to the DE Medical Equipment industry average.
PE vs Market: 2FV is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2FV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2FV is good value based on its PB Ratio (2.5x) compared to the DE Medical Equipment industry average (4.4x).
How is ScandiDos forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ScandiDos has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine ScandiDos's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- ScandiDos competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has ScandiDos performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2FV is currently unprofitable.
Growing Profit Margin: 2FV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2FV is unprofitable, but has reduced losses over the past 5 years at a rate of 1.9% per year.
Accelerating Growth: Unable to compare 2FV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2FV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.8%).
Return on Equity
High ROE: 2FV has a negative Return on Equity (-28.39%), as it is currently unprofitable.
How is ScandiDos's financial position?
Financial Position Analysis
Short Term Liabilities: 2FV's short term assets (SEK38.0M) exceed its short term liabilities (SEK24.7M).
Long Term Liabilities: 2FV has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 2FV's debt to equity ratio (3.8%) is considered satisfactory.
Reducing Debt: 2FV's debt to equity ratio has reduced from 18.2% to 3.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2FV has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 2FV has less than a year of cash runway if free cash flow continues to grow at historical rates of 2% each year.
What is ScandiDos's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2FV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2FV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2FV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2FV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2FV's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gustaf Piehl (42 yo)
Mr. Gustaf Piehl serves as Chief Executive Officer at ScandiDos AB (publ) since September 2020. He Gustaf has many years of experience in the radiation therapy industry after holding a number of different ...
|Technical Manager||no data||kr1.99m||no data|
|Deputy CEO & Director||5.67yrs||kr1.23m||no data|
|Chief Executive Officer||no data||no data||no data|
|Chief Financial Officer||8.67yrs||no data||no data|
|Marketing Manager||3.92yrs||no data||no data|
|Vice President of Sales||1.08yrs||no data||no data|
Experienced Management: 2FV's management team is seasoned and experienced (6.3 years average tenure).
|Deputy CEO & Director||5.67yrs||kr1.23m||no data|
|Director||no data||kr100.00k||no data|
|Chairman of the Board||5.67yrs||kr250.00k||no data|
Experienced Board: 2FV's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ScandiDos AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: ScandiDos AB (publ)
- Ticker: 2FV
- Exchange: DB
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr117.743m
- Listing Market Cap: kr11.301m
- Shares outstanding: 41.46m
- Website: https://scandidos.com
Number of Employees
- ScandiDos AB (publ)
- Uppsala Science Park
- 751 83
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SDOS||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Apr 2014|
|2FV||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||Apr 2014|
ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. The company offers Delta4 Family soluti ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/24 04:06|
|End of Day Share Price||2020/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.